RAPT
RAPT Therapeutics, Inc.NASDAQHealthcare$58.01+0.00%ClosedMarket Cap: $959.3M
As of 2026-04-04
Valuation
P/E (TTM)
—
PEG
—
P/B
10.29
P/S
0.00
EV/EBITDA
-8.55
DCF Value
$32.20
FCF Yield
-9.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-61.8%
ROA
-63.7%
ROIC
-72.9%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q3 2025 | $0.00 | NaN% | $-19.4M | $-17.6M | $-0.65 | — |
| Q2 2025 | $0.00 | -Infinity% | $-19.5M | $-17.6M | $-0.65 | — |
| Q1 2025 | $0.00 | NaN% | $-19.3M | $-17.2M | $-0.64 | — |
| Q4 2024 | $0.00 | NaN% | $-54.5M | $-53.2M | $-9.12 | — |
| FY 2024 | $0.00 | NaN% | $-136.1M | $-129.9M | $-25.49 | — |
| Q3 2024 | $0.00 | NaN% | $-19.8M | $-18.4M | $-3.79 | — |
| Q2 2024 | $0.00 | NaN% | $-29.3M | $-27.7M | $-5.69 | — |
| Q1 2024 | $0.00 | -Infinity% | $-32.5M | $-30.5M | $-6.32 | — |
| Q4 2023 | $0.00 | NaN% | $-33.2M | $-30.9M | $-6.44 | — |
| FY 2023 | $0.00 | NaN% | $-127.1M | $-116.8M | $-24.37 | — |
| Q3 2023 | $0.00 | NaN% | $-33.9M | $-31.4M | $-6.54 | — |
| Q2 2023 | $0.00 | NaN% | $-28.4M | $-25.3M | $-5.28 | — |